Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Tencent Music Entertainment Group - ADR — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Tencent Music Entertainment Group - ADR trades at $8.32 (market cap $13.81B). The key difference: Tencent Music Entertainment Group - ADR is the larger of the two by market cap, and Tencent Music Entertainment Group - ADR pays a 2.82% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Tencent Music Entertainment Group - ADR for 68 Days on average.
| SYRE | TME | |
|---|---|---|
Market Cap | $7.52B | $13.81B |
Volume | 1,441,031 | 6,097,902 |
Sector | Health | Media |
52-Week High | $108.92 | $23.71 |
52-Week Low | $22.18 | $7.74 |
Typical Hold Time | 0 Days | 68 Days |
Enterprise Value | $6.52B | $11.76B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Tencent Music Entertainment (TME) trades at $8.48, up 0.36% on the day, with a bullish technical signal and strong fundamentals. Revenue grew to $32.9B in 2025, with net income surging to $11.06B, and valuation ratios like a P/E of 9.94 appear attractive. Recent news highlights a $1B notes offering and a $400M share repurchase program, signaling financial discipline.
The outlook is positive with a consensus price target of $12.50, offering 47% upside, but risks include intense competition and regulatory oversight. Earnings have been mixed, with Q2 2026 beating expectations but Q1 and Q4 2025 missing, indicating potential volatility in performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
